Home » OrthoSera Receives CE Mark for hypACT Device to Restore Osteoarthritic Bone
OrthoSera Receives CE Mark for hypACT Device to Restore Osteoarthritic Bone
Austria-based orthobiologics company OrthoSera has received EU market authorization for its autologous hypACT injection device, which is available for clinical use.
The company has developed a hyperacute serum technology to be used to treat osteoarthritis and other degenerative diseases and is to be administered through the hypACT device.
The device isolates a specific serum derivative (SPRF) from the patient in a closed system, which is then applied during a same-day-procedure. — Cynthia Jessup
Upcoming Events
-
07May
-
14May
-
30May